Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Securities Case
December 08, 2016 11:06 ET | Scott + Scott, Attorneys at Law, LLP
NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to...
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Securities Case
November 08, 2016 10:53 ET | Scott + Scott, Attorneys at Law, LLP
NEW YORK, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to file...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports First Quarter 2016 Financial Results
May 09, 2016 16:10 ET | Agile Therapeutics, Inc.
Cash Expected to Fund Operations through the End of 2017Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 ...
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
February 02, 2016 08:00 ET | AbCellera
JERUSALEM and VANCOUVER, British Columbia, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera have entered into a collaborative research...
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
September 29, 2015 21:10 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for...
Mesoblast Unveils Path to Bring Its Key Products to Market
August 25, 2014 20:27 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its...
Mesoblast Reports Strong Half-Year Financial Results
February 25, 2014 17:00 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...
FDA CLEARS COMMENCEMENT OF PHASE 3 CHRONIC HEART FAILURE TRIAL USING MESOBLAST'S PROPRIETARY CELLS
October 30, 2013 18:41 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Food and Drug...
Mesoblast's Strong Cash Position Enables Execution of Late-Stage Clinical Trials
August 29, 2013 00:42 ET | Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 29, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company, Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY), today provided its full year financial results. The...
Houston Colorectal Surgeon Provides Incisionless Technique to Remove Rectal Tumors
May 02, 2013 06:03 ET | Colorectal Surgical Associates
HOUSTON, TX--(Marketwired - May 2, 2013) - Houston colorectal surgeon Dr. Eric Haas and his team at Colorectal Surgical Associates are now offering patients an incisionless and minimally-invasive...